NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Akebia Therapeutics Inc (NASDAQ: AKBA)

 
AKBA Technical Analysis
1
As on 9th Jun 2023 AKBA STOCK Price closed @ 1.26 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

AKBASTOCK Price

Open 1.25 Change Price %
High 1.27 1 Day N/A N/A
Low 1.21 1 Week 0.00 0.00
Close 1.26 1 Month 0.00 0.00
Volume 961900 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
NASDAQ USA Most Active Stocks
TSLA 244.40 %
TTOO 0.07 %
SOFI 8.18 %
FFIE 0.33 %
PONO 1.72 2.38%
AMD 124.92 %
IDEX 0.06 %
NKLA 0.70 %
AMZN 123.43 %
AAPL 180.96 %
 
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
GLSPT 33.43 138.62%
BCAC 22.71 125.30%
JCIC 22.08 116.68%
SBEAW 2.05 51.85%
BRPMW 0.94 46.88%
BSGAU 11.29 41.12%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
MILEW 0.06 -53.85%
BTAQW 0.01 -50.00%
ALACW 0.01 -50.00%
ALF 0.01 -50.00%
ALF 0.01 -50.00%
LOTZW 0.01 -50.00%
IGNY 6.98 -46.51%
IGNYW 0.17 -45.16%
 
 
AKBA
Daily Charts
AKBA
Intraday Charts
Whats New @
Bazaartrend
AKBA
Free Analysis
 
AKBA Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
AKBA Forecast September 2023
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
AKBA Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
AKBA Forecast2023
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
AKBA Other Details
Segment EQ
Market Capital 495685056.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
AKBA Address
AKBA
 
AKBA Latest News
 
Your Comments and Response on Akebia Therapeutics Inc
 
AKBA Business Profile
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 245 First Street, Cambridge, MA, United States, 02142
 
2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service